ARS Pharmaceuticals, Inc. (SPRY) Misses Q2 EPS by 1c

ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) reported Q2 EPS of ($0.13), $0.01 worse than the analyst estimate of ($0.12). Revenue for the quarter came in at $500 thousand versus the consensus estimate of $1 million.

For earnings history and earnings-related data on ARS Pharmaceuticals, Inc. (SPRY) click here.

You May Also Be Interested In

• Attention Long-Term Shareholders of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY); Bloom Energy Corporation (NYSE: BE); Erasca, Inc. (NASDAQ: ERAS); and Insulet Corporation (NASDAQ: PODD): Grabar Law Offic
• H.C. Wainwright Reiterates Buy Rating on Jasper Therapeutics (JSPR)
• Haemonetics signs non-exclusive supply deal with CSL Plasma